Nao Ichihara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nao Ichihara has a total of 332 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Miyata
Department of Healthcare Quality Assessment, University of Tokyo, Bunkyo, Tokyo, Japan
11 shared publications- Hideki Endo
Department of Healthcare Quality Assessment, Graduate School of Medicine The University of Tokyo Tokyo Japan
5 shared publications - Hiraku Kumamaru
Department of Healthcare Quality Assessment The University of Tokyo Graduate School of Medicine Bunkyo Tokyo Japan
4 shared publications - Hiroaki Miyata
Department of Health Policy and Management, Keio University School of Medicine, Tokyo 160-8582, Japan
4 shared publications - Hiroyuki Yamamoto
National Clinical Database Steering Committee of Japanese Urological Association Tokyo Japan
4 shared publications Yuko Kitagawa
The Japanese Society of Gastroenterological Surgery Tokyo Japan
4 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1546-1562
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Objective: To determine whether ivermectin improves outcomes for critically and noncritically ill hospitalized patients with COVID-19. Design: An ongoing international, multifactorial, adaptive platform, randomized, controlled trial. Setting: Hospitals in Pakistan, India, and Ireland between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Results: The primary outcome was respiratory and cardiovascular organ support-free days, assessed on an ordinal scale combining in-hospital death (assigned a value of –1) and days free of organ support through day 21 in survivors. Analyses used a Bayesian cumulative logistic model. Enrollment was closed for operational futility, following external evidence suggesting no benefit with ivermectin in nonhospitalized patients with COVID-19. Among 61 critically ill patients, the median number of organ support-free days was –1, indicating death was the most common vital outcome (interquartile range [IQR], –1 to 17), for the ivermectin group and –1 (IQR, –1 to 17.25) for the control group (adjusted proportional odds ratio [OR], 0.94; 95% credible interval [CrI], 0.40–2.07) and the posterior probability of superiority to control was 44.2%. Among 89 noncritically ill patients, the median number of organ support-free days was 22 (IQR, 18.5–22) for ivermectin and 22 (IQR, 16–22) for control (adjusted proportional OR, 1.04; 95% CrI, 0.48–2.34) and the posterior probability of superiority was 53.7%. Among critically ill patients, hospital survival was 35.1% (13/37) for ivermectin and 37.5% (9/24) for control (adjusted OR, 1.00; 95% CrI, 0.39–2.32), posterior probability of superiority was 50.0%. Among noncritically ill patients, hospital survival was 84.1% (37/44) for ivermectin and 77.8% (35/45) for control (adjusted OR, 1.16; 95% CrI, 0.5–3.07), posterior probability of superiority was 63.3%. Conclusions: For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival.
- 8 May 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (7) , 1546-1562
Open AccessIvermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
Objective: To determine whether ivermectin improves outcomes for critically and noncritically ill hospitalized patients with COVID-19. Design: An ongoing international, multifactorial, adaptive platform, randomized, controlled trial. Setting: Hospitals in Pakistan, India, and Ireland between June 11, 2021, and September 9, 2022. Patients: Critically and noncritically ill patients. Interventions: Randomized to ivermectin or no ivermectin (control). Measurements and Main Results: The primary outcome was respiratory and cardiovascular organ support-free days, assessed on an ordinal scale combining in-hospital death (assigned a value of –1) and days free of organ support through day 21 in survivors. Analyses used a Bayesian cumulative logistic model. Enrollment was closed for operational futility, following external evidence suggesting no benefit with ivermectin in nonhospitalized patients with COVID-19. Among 61 critically ill patients, the median number of organ support-free days was –1, indicating death was the most common vital outcome (interquartile range [IQR], –1 to 17), for the ivermectin group and –1 (IQR, –1 to 17.25) for the control group (adjusted proportional odds ratio [OR], 0.94; 95% credible interval [CrI], 0.40–2.07) and the posterior probability of superiority to control was 44.2%. Among 89 noncritically ill patients, the median number of organ support-free days was 22 (IQR, 18.5–22) for ivermectin and 22 (IQR, 16–22) for control (adjusted proportional OR, 1.04; 95% CrI, 0.48–2.34) and the posterior probability of superiority was 53.7%. Among critically ill patients, hospital survival was 35.1% (13/37) for ivermectin and 37.5% (9/24) for control (adjusted OR, 1.00; 95% CrI, 0.39–2.32), posterior probability of superiority was 50.0%. Among noncritically ill patients, hospital survival was 84.1% (37/44) for ivermectin and 77.8% (35/45) for control (adjusted OR, 1.16; 95% CrI, 0.5–3.07), posterior probability of superiority was 63.3%. Conclusions: For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival.
- Open Access
- 18 December 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260168
Characteristics of intensive care unit registries - findings from the Global Registry ICU Datasets (GRID) survey
Intensive care unit registries, which aim to improve the quality of intensive care unit care through benchmarking and quality improvement initiatives, are active worldwide, with considerable dishomogeneity. We aimed to map core datasets, additional variables, and research activities of these registries. A cross-sectional survey was disseminated to registry leads between October 2023 and June 2024. The survey was structured into four main topics: registry characteristics and coverage, core dataset features, additional modules, and registry-enabled research. Leads of 34/42 national registries responded (response rate 81%), covering 3,337 intensive care units, with a larger representation from South America. Systematized nomenclature of medicine, clinical terms, and customized categorical classifications were the main nomenclatures used. All registries except one employed a severity of illness score/risk prediction model. The SOFA score was reported by 88% of registries. Organ support measures were often recorded, including mechanical ventilation (97%), vasopressor administration (86%) and renal replacement therapy (86%). Three out of four intensive care unit registries coded interventions such as intubations, intravenous lines and tracheostomies. Additional datasets differed, with many use cases for nosocomial infection burden, bed availability and staffing resources. Over half of intensive care unit registries had current structured quality improvement initiatives. Registry-enabled observational research was reported in 46% of registries, while interventional studies were reported in only 22%. Over three thousand intensive care units in 35 countries participate in an intensive care unit registry. Despite heterogeneity in coding systems, risk models, and additional datasets, we identify several areas of convergence that may inform a future shared core dataset. There is potential for further intensive care unit registry-based research, particularly interventional.
- 18 December 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 38, e20260168
Open AccessCharacteristics of intensive care unit registries - findings from the Global Registry ICU Datasets (GRID) survey
Intensive care unit registries, which aim to improve the quality of intensive care unit care through benchmarking and quality improvement initiatives, are active worldwide, with considerable dishomogeneity. We aimed to map core datasets, additional variables, and research activities of these registries. A cross-sectional survey was disseminated to registry leads between October 2023 and June 2024. The survey was structured into four main topics: registry characteristics and coverage, core dataset features, additional modules, and registry-enabled research. Leads of 34/42 national registries responded (response rate 81%), covering 3,337 intensive care units, with a larger representation from South America. Systematized nomenclature of medicine, clinical terms, and customized categorical classifications were the main nomenclatures used. All registries except one employed a severity of illness score/risk prediction model. The SOFA score was reported by 88% of registries. Organ support measures were often recorded, including mechanical ventilation (97%), vasopressor administration (86%) and renal replacement therapy (86%). Three out of four intensive care unit registries coded interventions such as intubations, intravenous lines and tracheostomies. Additional datasets differed, with many use cases for nosocomial infection burden, bed availability and staffing resources. Over half of intensive care unit registries had current structured quality improvement initiatives. Registry-enabled observational research was reported in 46% of registries, while interventional studies were reported in only 22%. Over three thousand intensive care units in 35 countries participate in an intensive care unit registry. Despite heterogeneity in coding systems, risk models, and additional datasets, we identify several areas of convergence that may inform a future shared core dataset. There is potential for further intensive care unit registry-based research, particularly interventional.
- Open Access
- 2 September 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-10
Career advancement and fertility intention among working women in Japan: a cross-sectional survey study
The global decline in birth rates highlights the need to understand fertility intention among working women of childbearing age. However, only few studies have examined the balance between career and childbearing in Japan, which has a rapidly aging society. This study aimed to explore factors influencing fertility intention by evaluating health status, healthcare access, career advancements, working conditions, and workplace dynamics among Japanese working women. This cross-sectional study used data from the Working Women’s Health Score survey, a collaboration between industry and academia, aimed at evaluating female employees’ health and working environments at 14 companies. Participants were women aged 19–65 years working at companies in the Marunouchi area of Tokyo, Japan. A total of 3,425 women completed an online health survey between September 13 and October 11, 2022. The survey collected information on demographic characteristics, childbearing status and intentions, health status, gynecological history, lifestyle, healthy habits, working styles, and workplace environments. To identify factors associated with childbearing intention, working women under 40 years (n = 1,621) were categorized as those with and those without fertility intention. Participants with children who wished to have more children in the future were assigned to the fertility intention group. Women in the fertility intention group were more likely to be younger, married, and proactive about their health. They reported greater confidence in their physical health and better sleep quality. No significant differences were observed between the groups regarding severity of dysmenorrhea, premenstrual syndrome, or overall health literacy. Women in the fertility intention group were more likely to be regular full-time workers, work in sales rather than clerical positions, and be more motivated for career advancement. Workplace environment factors, including job engagement and male colleagues’ understanding of female-specific symptoms, did not significantly differ between the two groups. Job stability, job type, career motivation, confidence, and proactive health management are associated with fertility intention among working women in Japan. Women assured of career advancement may also be more inclined to plan for childbearing, highlighting the importance of workplace policies supporting career development and family planning.
- 2 September 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-10
Open AccessCareer advancement and fertility intention among working women in Japan: a cross-sectional survey study
The global decline in birth rates highlights the need to understand fertility intention among working women of childbearing age. However, only few studies have examined the balance between career and childbearing in Japan, which has a rapidly aging society. This study aimed to explore factors influencing fertility intention by evaluating health status, healthcare access, career advancements, working conditions, and workplace dynamics among Japanese working women. This cross-sectional study used data from the Working Women’s Health Score survey, a collaboration between industry and academia, aimed at evaluating female employees’ health and working environments at 14 companies. Participants were women aged 19–65 years working at companies in the Marunouchi area of Tokyo, Japan. A total of 3,425 women completed an online health survey between September 13 and October 11, 2022. The survey collected information on demographic characteristics, childbearing status and intentions, health status, gynecological history, lifestyle, healthy habits, working styles, and workplace environments. To identify factors associated with childbearing intention, working women under 40 years (n = 1,621) were categorized as those with and those without fertility intention. Participants with children who wished to have more children in the future were assigned to the fertility intention group. Women in the fertility intention group were more likely to be younger, married, and proactive about their health. They reported greater confidence in their physical health and better sleep quality. No significant differences were observed between the groups regarding severity of dysmenorrhea, premenstrual syndrome, or overall health literacy. Women in the fertility intention group were more likely to be regular full-time workers, work in sales rather than clerical positions, and be more motivated for career advancement. Workplace environment factors, including job engagement and male colleagues’ understanding of female-specific symptoms, did not significantly differ between the two groups. Job stability, job type, career motivation, confidence, and proactive health management are associated with fertility intention among working women in Japan. Women assured of career advancement may also be more inclined to plan for childbearing, highlighting the importance of workplace policies supporting career development and family planning.
- Open Access
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.
- 1 July 2025
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Open AccessBuilding an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.
- 5 March 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (6) , 1372-1382
How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic
With the coronavirus disease 2019 (COVID‐19) pandemic, there is growing interest in utilizing adaptive platform clinical trials (APTs), in which multiple drugs are compared with a single common control group, such as a placebo or standard‐of‐care group. APTs evaluate several drugs for one disease and accept additions or exclusions of drugs as the trials progress; however, little is known about the efficiency of APTs over multiple stand‐alone trials. In this study, we simulated the total development period, total sample size, and statistical operating characteristics of APTs and multiple stand‐alone trials in drug development settings for hospitalized patients with COVID‐19. Simulation studies using selected scenarios reconfirmed several findings regarding the efficiency of APTs. The APTs without staggered addition of drugs showed a shorter total development period than stand‐alone trials, but the difference rapidly diminished if patient's enrollment was accelerated during the trials owing to the spread of infection. APTs with staggered addition of drugs still have the possibility of reducing the total development period compared with multiple stand‐alone trials in some cases. Our study demonstrated that APTs could improve efficiency relative to multiple stand‐alone trials regarding the total development period and total sample size without undermining statistical validity; however, this improvement varies depending on the speed of patient enrollment, sample size, presence/absence of family‐wise error rate adjustment, allocation ratio between drug and placebo groups, and interval of staggered addition of drugs. Given the complexity of planning and implementing APT, the decision to implement APT during a pandemic must be made carefully.
- 5 March 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (6) , 1372-1382
How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand‐Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic
With the coronavirus disease 2019 (COVID‐19) pandemic, there is growing interest in utilizing adaptive platform clinical trials (APTs), in which multiple drugs are compared with a single common control group, such as a placebo or standard‐of‐care group. APTs evaluate several drugs for one disease and accept additions or exclusions of drugs as the trials progress; however, little is known about the efficiency of APTs over multiple stand‐alone trials. In this study, we simulated the total development period, total sample size, and statistical operating characteristics of APTs and multiple stand‐alone trials in drug development settings for hospitalized patients with COVID‐19. Simulation studies using selected scenarios reconfirmed several findings regarding the efficiency of APTs. The APTs without staggered addition of drugs showed a shorter total development period than stand‐alone trials, but the difference rapidly diminished if patient's enrollment was accelerated during the trials owing to the spread of infection. APTs with staggered addition of drugs still have the possibility of reducing the total development period compared with multiple stand‐alone trials in some cases. Our study demonstrated that APTs could improve efficiency relative to multiple stand‐alone trials regarding the total development period and total sample size without undermining statistical validity; however, this improvement varies depending on the speed of patient enrollment, sample size, presence/absence of family‐wise error rate adjustment, allocation ratio between drug and placebo groups, and interval of staggered addition of drugs. Given the complexity of planning and implementing APT, the decision to implement APT during a pandemic must be made carefully.
- 9 December 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-9
Male sex and presence of preoperative symptoms are associated with early recurrence of WHO grade I meningiomas after surgical resection: analysis from the nationwide Brain Tumor Registry of Japan
This study aimed to assess the risk factors for the recurrence of WHO grade I intracranial meningiomas using the Brain Tumor Registry of Japan (BTRJ) database. We extracted the data of 4641 patients with intracranial WHO grade I meningiomas treated only by surgical resection between 2001 and 2008. We conducted complete data analysis (n = 3690) and multiple imputation analysis (n = 4641) to adjust for missing data on tumor size. The influence of factors including age, sex, size, extent of resection, location, and preoperative symptoms on PFS was assessed. Univariate analyses of the complete data set showed that age did not affect PFS; however, male sex (p < 0.001), tumor size >= 30 mm (p < 0.001), low extent of resection, tumor location at the skull base (p < 0.001), and the presence of preoperative symptoms (p < 0.001) were risk factors for a significantly shorter PFS. Multivariate analysis demonstrated that male sex (p < 0.001) and presence of preoperative symptoms (p = 0.027) were independent risk factors for shorter PFS alongside large tumor size (p < 0.001) and non-gross total resection (p < 0.001). These results were confirmed for the imputed dataset. While most previous large nationwide studies of meningiomas have evaluated overall survival, progression-free survival has yet to be thoroughly examined. This study suggests that even histologically benign meningiomas may have a sex difference in postoperative behavior. This observation may provide clues to understanding the mechanism of meningioma cell proliferation.
- 9 December 2023
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-9
Male sex and presence of preoperative symptoms are associated with early recurrence of WHO grade I meningiomas after surgical resection: analysis from the nationwide Brain Tumor Registry of Japan
This study aimed to assess the risk factors for the recurrence of WHO grade I intracranial meningiomas using the Brain Tumor Registry of Japan (BTRJ) database. We extracted the data of 4641 patients with intracranial WHO grade I meningiomas treated only by surgical resection between 2001 and 2008. We conducted complete data analysis (n = 3690) and multiple imputation analysis (n = 4641) to adjust for missing data on tumor size. The influence of factors including age, sex, size, extent of resection, location, and preoperative symptoms on PFS was assessed. Univariate analyses of the complete data set showed that age did not affect PFS; however, male sex (p < 0.001), tumor size >= 30 mm (p < 0.001), low extent of resection, tumor location at the skull base (p < 0.001), and the presence of preoperative symptoms (p < 0.001) were risk factors for a significantly shorter PFS. Multivariate analysis demonstrated that male sex (p < 0.001) and presence of preoperative symptoms (p = 0.027) were independent risk factors for shorter PFS alongside large tumor size (p < 0.001) and non-gross total resection (p < 0.001). These results were confirmed for the imputed dataset. While most previous large nationwide studies of meningiomas have evaluated overall survival, progression-free survival has yet to be thoroughly examined. This study suggests that even histologically benign meningiomas may have a sex difference in postoperative behavior. This observation may provide clues to understanding the mechanism of meningioma cell proliferation.
- Open Access
- 20 September 2023
- Published by Elsevier in Resuscitation Plus
- Vol. 16, 100474
Frequency, clinical characteristics, and outcomes of pneumonia in patients with out-of-hospital cardiac arrest undergoing extracorporeal cardiopulmonary resuscitation
- 20 September 2023
- Published by Elsevier in Resuscitation Plus
- Vol. 16, 100474
Open AccessFrequency, clinical characteristics, and outcomes of pneumonia in patients with out-of-hospital cardiac arrest undergoing extracorporeal cardiopulmonary resuscitation
- 15 April 2023
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 85 (6) , 1396-1401
An Analysis of Surgical Procedures for Trauma from the National Clinical Database in Japan, 2011–2016
- 15 April 2023
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 85 (6) , 1396-1401
An Analysis of Surgical Procedures for Trauma from the National Clinical Database in Japan, 2011–2016
- Open Access
- 20 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0280569
Achieving clinically optimal balance between accuracy and simplicity of a formula for manual use: Development of a simple formula for estimating liver graft weight with donor anthropometrics
In developing a formula for manual use in clinical settings, simplicity is as important as accuracy. Whole-liver (WL) mass is often estimated using demographic and anthropometric information to calculate the standard liver volume or recommended graft volume in liver transplantation. Multiple formulas for estimating WL mass have been reported, including those with multiple independent variables. However, it is unknown whether multivariable models lead to clinically meaningful improvements in accuracy over univariable models. Our goal was to quantitatively define clinically meaningful improvements in accuracy, which justifies an additional independent variable, and to identify an estimation formula for WL graft weight that best balances accuracy and simplicity given the criterion. From the Japanese Liver Transplantation Society registry, which contains data on all liver transplant cases in Japan, 129 WL donor-graft pairs were extracted. Among the candidate models, those with the smallest cross-validation (CV) root-mean-square error (RMSE) were selected, penalizing model complexity by requiring more complex models to yield a ≥5% decrease in CV RMSE. The winning model by voting with random subsets was fitted to the entire dataset to obtain the final formula. External validity was assessed using CV. A simple univariable linear regression formula using body weight (BW) was obtained as follows: WL graft weight [g] = 14.8 × BW [kg] + 439.2. The CV RMSE (g) and coefficient of determination (R2) were 195.2 and 0.548, respectively. In summary, in the development of a simple formula for manually estimating WL weight using demographic and anthropometric variables, a clinically acceptable trade-off between accuracy and simplicity was quantitatively defined, and the best model was selected using this criterion. A univariable linear model using BW achieved a clinically optimal balance between simplicity and accuracy, while one using body surface area performed similarly.
- 20 January 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (1) , e0280569
Open AccessAchieving clinically optimal balance between accuracy and simplicity of a formula for manual use: Development of a simple formula for estimating liver graft weight with donor anthropometrics
In developing a formula for manual use in clinical settings, simplicity is as important as accuracy. Whole-liver (WL) mass is often estimated using demographic and anthropometric information to calculate the standard liver volume or recommended graft volume in liver transplantation. Multiple formulas for estimating WL mass have been reported, including those with multiple independent variables. However, it is unknown whether multivariable models lead to clinically meaningful improvements in accuracy over univariable models. Our goal was to quantitatively define clinically meaningful improvements in accuracy, which justifies an additional independent variable, and to identify an estimation formula for WL graft weight that best balances accuracy and simplicity given the criterion. From the Japanese Liver Transplantation Society registry, which contains data on all liver transplant cases in Japan, 129 WL donor-graft pairs were extracted. Among the candidate models, those with the smallest cross-validation (CV) root-mean-square error (RMSE) were selected, penalizing model complexity by requiring more complex models to yield a ≥5% decrease in CV RMSE. The winning model by voting with random subsets was fitted to the entire dataset to obtain the final formula. External validity was assessed using CV. A simple univariable linear regression formula using body weight (BW) was obtained as follows: WL graft weight [g] = 14.8 × BW [kg] + 439.2. The CV RMSE (g) and coefficient of determination (R2) were 195.2 and 0.548, respectively. In summary, in the development of a simple formula for manually estimating WL weight using demographic and anthropometric variables, a clinically acceptable trade-off between accuracy and simplicity was quantitatively defined, and the best model was selected using this criterion. A univariable linear model using BW achieved a clinically optimal balance between simplicity and accuracy, while one using body surface area performed similarly.
- 9 December 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 154, 56-64
Recalibration of prediction model was needed for monitoring health care quality in subgroups: a retrospective cohort study
- 9 December 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 154, 56-64
Recalibration of prediction model was needed for monitoring health care quality in subgroups: a retrospective cohort study